Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Arbutus Biopharma Corporation